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Sleep is a major emerging area of interest in neurodegenerative diseases. A compelling case 
has been made that sleep disruption contributes to the pathogenesis of Alzheimer’s disease 
(AD)[1]. In this paper we draw attention to mounting recent evidence that disordered 
sleep is a feature of diverse neurodegenerative diseases besides AD, and may differentiate 
these diseases on clinical, electrophysiological and neurohormonal grounds[2-8]. In addition 
to well-recognised sleep phenotypes of Parkinson’s and prion disease, clinical sleep 
disturbance and disordered sleep architecture are increasingly reported in the frontotemporal 
dementia (FTD) spectrum[2,3]. 
 
 
 
FTD is an informative test case that assesses the wider pathophysiological relevance of sleep 
in proteinopathies. Clinically, patients with FTD commonly develop excessive somnolence as 
well as narcolepsy-like attacks, insomnia and other sleep-related symptoms[2,4]; sleep 
disturbance may be more prevalent in FTD than in AD[4] and forms part of a broader 
repertoire of chronobiological and autonomic symptoms[4]. FTD is associated 
electrophysiologically, with disruption of macro- and micro-structural parameters that may 
be more severe and occur earlier than in AD[5]. AD and FTD show divergent profiles of 
hypothalamic neuropeptide alterations; whereas AD may be uniquely associated with 
elevated orexin levels[1], FTD is associated with reduced plasma and CSF orexin that 
correlates with excessive daytime somnolence[2,3]. In addition to differentiating AD from 
non-AD (FTD) pathologies, sleep phenotype may further stratify proteinopathies within the 
FTD spectrum, as exemplified by genetically-mediated forms of FTD. Mutation of the MAPT 
gene has been linked to severe insomnia, sleep fragmentation, reduced REM latency and slow-
wave sleep while mutation of the C9orf72 gene may be associated with REM-behaviour 
disorder [6-8], corroborated in mouse models[9]. 
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We propose that sleep-related processes are integral to the pathogenesis of neurodegenerative 
diseases. Sleep may translate the effects of pathogenic protein spread in vulnerable neuronal 
populations to the large-scale neural ensembles that drive clinical phenotypes. We outline this 
idea in Figure 1. Because neurodegenerative proteinopathies preferentially target particular 
neural systems (at least earlier in the course of disease) and these same systems are often 
integrally involved in circadian cycling, the pathophysiological effects of sleep disturbance 
– and more specifically, impairment of restorative or reparative sleep processes acting at 
synaptic level – will tend to be focused within the vulnerable circuitry that triggers the 
sleep derangement[1,10]. This would create a substrate for vicious cycling, with amplification 
of dysfunction leading ultimately to cell death – and further sleep disruption. If this idea is 
correct, sleep disturbance is a potential driver of neurodegeneration in a range of 
proteinopathies. 
 
 
 
We assert that further work to assess the implications of disordered sleep in dementia is 
urgently required, and this should entail a broadening of vision beyond AD to other 
neurodegenerative diseases whose hypnic phenotypes have not yet been fully characterised. 
There is a need to establish the relation of sleep disruption to other disease markers and to 
assess the extent to which sleep phenotype may predict the evolution of neurodegeneration 
across proteinopathies (and might differentiate particular proteinopathies). This will entail 
head-to-head comparison of diseases with molecular correlation in longitudinal natural history 
studies and the further development of animal models and computational approaches that will 
allow sleep parameters to be directly manipulated. Because sleep disturbance is so common in 
the population at large, identification of a useful hypnic biomarker of neurodegeneration may 
require isolation of a disease-specific microarchitectural feature of the sleep phenotype or a 
feature that (while not specific) indexes disease progression in the clinical context. A number 
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of vistas of sleep physiology remain under-explored in neurodegenerative populations but 
might be anticipated on clinical grounds to yield novel insights into particular diseases. One 
example is the cognitive neuropsychology and functional neuroanatomy of dreaming: dreams 
may sensitively signal dysfunction of the large-scale neural networks that mediate sleep 
cycle transitions and may be particularly vulnerable to loss of visuospatial imagery in AD 
and its variant phenotypes, as well as to semantic and affective disintegration in syndromes 
of FTD. Besides the prospect of new clinical and laboratory biomarkers, defining hypnic 
mechanisms of proteinopathies promises to yield a powerful new pathophysiological 
paradigm of neurodegenerative disease. 
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Figure 1.  Hypnic signatures of neurodegenerative proteinopathies 
 
 
 
This cartoon of a mid-sagittal brain projection schematises the pathophysiological 
interaction of sleep-related neural circuitry with distributed networks targeted by 
Alzheimer’s disease (green) and non-Alzheimer proteinopathies in the frontotemporal 
dementia spectrum (red cross-hatched), in line with recent clinical and neurohormonal 
evidence [2-5,10]. In Alzheimer’s disease, cholinergic and other brainstem projection 
pathways in the isodendritic core (IC) preferentially target postero-medial cortex 
(PMC) and medial temporal lobe (mTL) structures including entorhinal cortex and 
hippocampus, while FTD proteinopathies preferentially target anterior cingulate cortex 
(ACC), basal orbitofrontal cortex (OFC) and anterior MTL structures connected to 
hypothalamus (h). Each of these proteinopathies disrupts interactions between 
brainstem, basal forebrain and hypothalamic cell populations involved in sleep and 
circadian cycling (bidirectional arrows): in Alzheimer’s disease, this may lead initially 
to compensatory increases in orexinergic activity with prominent insomnia, while in 
proteinopathies causing frontotemporal dementia, primary degeneration of orexinergic 
pathways may lead to excessive somnolence. In each case, loss of the restorative 
function of normal sleep focuses synaptic dysfunction in the projection zones targeted 
by the proteinopathy (long arrows), establishing a vicious cycle: sleep disturbance 
begets neurodegenerative damage which in turn begets further sleep disturbance. Both 
frontotemporal dementia and Alzheimer’s disease show considerable clinical 
heterogeneity and uniform sleep phenotypes of these diseases are therefore unlikely a 
priori. However, this highly over-simplified scheme predicts that sleep disturbance is 
a driver of the pathological process across neurodegenerative proteinopathies while 
specific sleep phenotypes may distinguish proteinopathies. 
 
